Elizabeth B Lamont
Biographic Data
| ID | 5535513 |
|---|---|
| NAME | Elizabeth B Lamont |
| GIVEN NAMES | Elizabeth B |
| FAMILY NAME | Lamont |
| SIGNATURE | LAMONT E B |
| AFFILIATIONS | Massachusetts General Hospital |
| ORCID | 0000-0001-6604-678X |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 7 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2002 |
| LATEST PUBLICATION YEAR | 2017 |
| H-INDEX | 0 |
Use of High-cost Systemic Treatments in Elderly mCRC Patients
Bradley, Cathy J. PhD*; Yabroff, K. Robin PhD†; Warren, Joan L. PhD†; Zeruto, Christopher BS‡; Chawla, Neetu PhD†; Lamont, Elizabeth B. MD§ Author Information
Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients
BACKGROUND: Little is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+. METHODS: We used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between…
Elderly Breast and Colorectal Cancer Patients’ Clinical Course
BACKGROUND: The social and medical environments that surround people are each independently associated with their cancer course. The extent to which these characteristics may together mediate patients' cancer care and outcomes is not known. METHODS: Using multilevel methods and data, we studied elderly breast and colorectal cancer patients (level I) within urban social (level II: ZIP code tabulation area) and health care (level III: hospital serv…
Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens
PURPOSE: We sought to determine the accuracy with which Medicare billing data documents elderly Medicare cancer patients' receipt of common multiagent chemotherapy regimens. METHODS: We merged gold-standard clinical trial data from 406 elderly cancer patients known to be treated on 1 of 6 Cancer and Leukemia Group B (CALGB) breast, colorectal, and lung cancer trials (trial numbers; 9344, 9730, 9235,9732, 80203, 89803) with their Medicare claims d…
Area-Level Variations in Cancer Care and Outcomes
BACKGROUND: : Substantial regional variations in health-care spending exist across the United States; yet, care and outcomes are not better in higher-spending areas. Most studies have focused on care in fee-for-service Medicare; whether spillover effects exist in settings without financial incentives for more care is unknown. OBJECTIVE: : We studied care for cancer patients in fee-for-service Medicare and the Veterans Health Administration (VA) t…
Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants
BACKGROUND: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. OBJECTIVE: Our goal was to determine whether the standard measures of toxicity used in clinical trials could be captured from observational Medicare claims data. METHODS: We identified 175 elderly clinical trial patients treated on 2 C…
Construct Validity of Medicare Chemotherapy Claims
BACKGROUND: The elderly are under represented in clinical trials of cancer therapy and the elderly who are enrolled may be unrepresentative. OBJECTIVE: To assess whether Medicare claims data might be used to understand the benefits and tolerance of chemotherapy in the general elderly population, the construct validity of Medicare 5FU claims for elderly colon cancer patients within the SEER-Medicare data set was determined. METHODS: In this valida…
No prominent works on this page.
Construct Validity of Medicare Chemotherapy Claims
BACKGROUND: The elderly are under represented in clinical trials of cancer therapy and the elderly who are enrolled may be unrepresentative. OBJECTIVE: To assess whether Medicare claims data might be used to understand the benefits and tolerance of chemotherapy in the general elderly population, the construct validity of Medicare 5FU claims for elderly colon cancer patients within the SEER-Medicare data set was determined. METHODS: In this valida…
Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants
BACKGROUND: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. OBJECTIVE: Our goal was to determine whether the standard measures of toxicity used in clinical trials could be captured from observational Medicare claims data. METHODS: We identified 175 elderly clinical trial patients treated on 2 C…
Area-Level Variations in Cancer Care and Outcomes
BACKGROUND: : Substantial regional variations in health-care spending exist across the United States; yet, care and outcomes are not better in higher-spending areas. Most studies have focused on care in fee-for-service Medicare; whether spillover effects exist in settings without financial incentives for more care is unknown. OBJECTIVE: : We studied care for cancer patients in fee-for-service Medicare and the Veterans Health Administration (VA) t…
Elderly Breast and Colorectal Cancer Patients’ Clinical Course
BACKGROUND: The social and medical environments that surround people are each independently associated with their cancer course. The extent to which these characteristics may together mediate patients' cancer care and outcomes is not known. METHODS: Using multilevel methods and data, we studied elderly breast and colorectal cancer patients (level I) within urban social (level II: ZIP code tabulation area) and health care (level III: hospital serv…
Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens
PURPOSE: We sought to determine the accuracy with which Medicare billing data documents elderly Medicare cancer patients' receipt of common multiagent chemotherapy regimens. METHODS: We merged gold-standard clinical trial data from 406 elderly cancer patients known to be treated on 1 of 6 Cancer and Leukemia Group B (CALGB) breast, colorectal, and lung cancer trials (trial numbers; 9344, 9730, 9235,9732, 80203, 89803) with their Medicare claims d…
Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients
BACKGROUND: Little is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+. METHODS: We used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between…
Use of High-cost Systemic Treatments in Elderly mCRC Patients
Bradley, Cathy J. PhD*; Yabroff, K. Robin PhD†; Warren, Joan L. PhD†; Zeruto, Christopher BS‡; Chawla, Neetu PhD†; Lamont, Elizabeth B. MD§ Author Information
Medicine (7 works) · Internal Medicine (5 works) · Internal Medicine (5 works) · Economic and Financial Impacts of Cancer (4 works) · Cancer (3 works) · Colorectal Cancer Treatments and Studies (3 works) · Global Cancer Incidence and Screening (3 works) · Oncology (3 works) · Oncology (3 works) · Chemotherapy (2 works)